Martin Pass, a former AstraZeneca Plc executive, has joined Amphista Therapeutics Ltd as chief development officer to lead work on targeted protein degradation. Prior to AstraZeneca, he was a medicinal chemist at GlaxoSmithKline Plc. He holds a PhD in organic chemistry from Imperial College London, UK and did post-doctoral research at the University of Virginia, US.
Amphista Therapeutics announced the appointment on 6 December 2021.
Copyright 2022 Evernow Publishing Ltd